Estrella Immunopharma, Inc. (ESLA) vs P3 Health Partners Inc. (PIII)
A side-by-side comparison of Estrella Immunopharma, Inc. and P3 Health Partners Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ESLA
Estrella Immunopharma, Inc.
$0.43HealthcareDelayed quote: Oct 6, 2026, 11:56 AM EDT
PIII
P3 Health Partners Inc.
$6.00HealthcareDelayed quote: Oct 6, 2026, 11:47 AM EDT
Total return — ESLA vs PIII
growth of $100 · dividends reinvested · last 5yESLA -95.5% (-46.2%/yr)PIII -98.7% (-58.3%/yr)ESLA compounded faster over this window
ESLA PIII
ESLA vs PIII: by the numbers
- •PIII is the larger company ($20M vs $18M market cap).
- •Both run net losses; ESLA's is the smaller (0.00% vs -6.55% net margin).
Metrics side by side
Valuation
| Metric | ESLA | PIII |
|---|---|---|
| P/S ratio | N/A | 0.01 |
Profitability
| Metric | ESLA | PIII |
|---|---|---|
| Gross margin | 0.00% | -9.89% |
| Operating margin | 0.00% | -18.53% |
| Net margin | 0.00% | -6.55% |
| ROE | N/A | -136.36% |
| ROIC | N/A | -51.68% |
Growth (annualized)
| Metric | ESLA | PIII |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 22.04% |
| Total return CAGR (5Y) | -46.34% | -58.41% |
Frequently asked
- How have ESLA and PIII total returns compared?
- Over the past 5 years, ESLA delivered -46.34% and PIII delivered -58.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Estrella Immunopharma ROEP3 Health Partners ROEEstrella Immunopharma operating marginP3 Health Partners operating marginEstrella Immunopharma revenue growthP3 Health Partners revenue growthEstrella Immunopharma free cash flowP3 Health Partners free cash flow
Estrella Immunopharma & P3 Health Partners appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.